Lantern Pharma Advances Pediatric Brain Cancer Treatment Using AI Platform – Citybuzz

Lantern Pharma Preps 2026 Trial for Rare Pediatric Brain Cancer After FDA Guidance

Dallas Innovates, Every Day: Here's what's new + next in North Texas. Lantern Pharma Inc. (Nasdaq: LTRN) said it plans to launch a clinical trial in early 2026 for a rare pediatric brain cancer, following what it called an “optimistic meeting” with the U.S. Food and Drug Administration. In an announcement, the Dallas-based biotech said the planned Phase 1b/2 trial will evaluate its drug candidate LP-184/STAR-001 in children with central nervous …

Lantern Pharma Advances Pediatric Brain Cancer Treatment Using AI Platform – citybuzz

Lantern Pharma Inc. (NASDAQ: LTRN) is advancing toward a clinical trial targeting rare pediatric brain cancers using its proprietary artificial intelligence platform and drug candidates. The company is preparing for the launch of a trial targeting a rare pediatric disease, planned for Q1 2026, following an optimistic meeting with the U.S. Food and Drug Administration that provided critical guidance on trial design and regulatory pathways. The co…